N Engl J Med
Paxlovid boosts recovery, but not major outcomes, after vaccination
Clinical takeaway: Paxlovid appears to shorten illness but not reduce hospitalization or death in vaccinated, higher-risk outpatients. These findings may support more selective use, rather than broad treatment in this population.
Paxlovid was originally adopted after showing a large reduction in hospitalization and death in unvaccinated high-risk adults, but its benefit in today’s more highly vaccinated populations has remained uncertain. These paired trials tested whether that earlier benefit still holds in community-dwelling adults at increased risk for severe COVID-19.
Researchers conducted two open-label platform trials (PANORAMIC and CanTreatCOVID) in the United Kingdom and Canada, enrolling adults age 50 or older, or younger adults with relevant coexisting conditions, who'd been symptomatic for 5 days or less. Participants were randomly assigned to usual care plus nirmatrelvir 300 mg and ritonavir 100 mg, the combination marketed as Paxlovid, twice daily for 5 days or to usual care alone.
Hospitalization or death within 28 days was rare in both trials and didn't differ significantly between groups. In PANORAMIC, the rate was 0.8% with Paxlovid and 0.7% with usual care; in CanTreatCOVID, it was 0.6% and 1.2%, respectively.
Recovery was faster with treatment in both studies. In PANORAMIC, median time to participant-reported recovery was 14 days with Paxlovid vs. 21 days with usual care. In CanTreatCOVID, median recovery time was 6 days vs. 9 days. In the PANORAMIC virology substudy, viral load at day 5 was 87% lower with Paxlovid than with usual care.
"In today's highly vaccinated populations, the benefits of Paxlovid have fundamentally changed," said Christopher Butler, MD, of Nuffield Department of Primary Care Health Sciences, University of Oxford, who led the UK trial. "While people feel better sooner from treatment with this important antiviral drug, we found no reduction in the already low rate of hospitalizations or deaths. This provides essential evidence for optimal, cost-effective targeting of this treatment."
Source: Butler CC. N Engl J Med. 2026 Apr 23. Oral nirmatrelvir-ritonavir for Covid-19 in higher-risk outpatients